Fig. 1.

ENESTfreedom study design. CML-CP chronic myeloid leukemia in chronic phase, DMR deep molecular response, MMR major molecular response [BCR-ABL1 on the International Scale (BCR-ABL1^IS) ≤ 0.1%], MR⁴ BCR-ABL1^IS ≤ 0.01%, MR^4.5 BCR-ABL1^IS ≤ 0.0032%, RQ-PCR real-time quantitative polymerase chain reaction, TFR treatment-free remission. ^aSustained DMR was defined as the following (in the last 4 quarterly RQ-PCR assessments): MR^4.5 in the last assessment, ≤ 2 assessments between MR⁴ and MR^4.5, and no assessment worse than MR⁴